This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Abclon Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Innovations of Hyun Jong Lee in Antibody Development
Introduction
Hyun Jong Lee is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibodies for medical applications. His work focuses on addressing angiogenesis-related diseases, which are critical areas of research in modern medicine.
Latest Patents
Hyun Jong Lee holds a patent for "Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease." This innovative antibody is designed for the prevention or treatment of macular degeneration and cancer, both of which are associated with abnormal blood vessel growth. The antibody specifically binds to VEGFR2, which is overexpressed in vascular endothelial cells. Notably, it exhibits very low homology compared to conventional VEGFR2 target antibodies, making it unique in its sequence. The efficacy of this antibody is comparable to that of ramucirumab, a standard treatment, highlighting its potential in clinical applications.
Career Highlights
Hyun Jong Lee is affiliated with Abclon Inc., a company dedicated to advancing biopharmaceutical innovations. His work at Abclon has positioned him as a key player in the development of therapeutic antibodies. With a focus on angiogenesis-related diseases, he has contributed to the growing body of research aimed at improving treatment options for patients.
Collaborations
Some of his notable coworkers include Jong Seo Lee and Kyu Tae Kim. Their collaborative efforts have further enhanced the research and development capabilities within their team, fostering an environment of innovation and discovery.
Conclusion
Hyun Jong Lee's contributions to antibody development represent a significant advancement in the treatment of angiogenesis-related diseases. His innovative approach and dedication to research continue to pave the way for future breakthroughs in biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile